Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

NCT04387461 is registered in ClinicalTrials.gov with CG Oncology, Inc. as lead sponsor.

NCT NCT04387461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04387461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Lead sponsor
CG Oncology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 8, 2020
Completion date
May 28, 2024
Enrollment
35 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

non muscle invasive bladder cancer